BizJournals |
August 29th, 2008 |
Email this
Aryx Therapeutics Inc. has appointed Amgen Inc. executive David Beier to its board of directors, the company said Friday. (ARYX)[...]
Seattle Times |
August 29th, 2008 |
Email this
Amgen will stop giving rebates to cancer clinics prescribing its anemia drug Aranesp to avoid what it called the "possible misperception"[...]
pharmalot |
August 28th, 2008 |
Email this
The biotech is responding to practices that were criticized for contributing to overuse of its flagship anemia drug at the same time safety concerns were growing, The New York Times reports. Specifically, Amgen will no longer offer rebates to oncology clinics for their use of Aranesp, although larger discounts will [...]
Amgen is halting some pricing practices that critics say were contributing to overuse of its flagship anemia drug Aranesp at a time of mounting concerns about the product’s safety.[...]
pharmalot |
August 27th, 2008 |
Email this
…more accustomed to backing Republican candidates for president. As the Democratic Convention builds to its unsurprising crescendo, a few drugmakers have tried to generate some political capital behind the scenes. For instance, Merck, Amgen, Pfizer, AstraZeneca, Novartis, Mylan Labs, Abbott Labs and Lilly all signed up as official sponsors. And [...]
Amgen has announced that the FDA has approved Nplate, the first and only platelet producer for the treatment of thrombocytopenia in splenectomized and non-splenectomized adults with chronic immune thrombocytopenic purpura.[...]
CNBC |
August 22nd, 2008 |
Email this
Federal regulators on Friday approved a biotech drug from Amgen Inc. to treat a rare blood-clotting disorder. Read More Permalink[...]
FierceBiotech |
August 22nd, 2008 |
Email this
Abbott is at it again. Last December, the Chicago-based company announced it was slashing 1,200 jobs. According to a report Abbott Laboratories filed with the Securities and Exchange Commission, the company will again be cutting 1,000 jobs (1.5 percent of its workforce) by 2011 in an effort to "streamline global manufacturing operations, [...]
Another big drug maker is going to start reporting how much grant money it doles out. GlaxoSmithKline said today that starting next year it will issue quarterly reports on its grants to "various organizations including hospitals, teaching institutions, managed care organizations, professional associations, patient advocacy groups, and continuing medical education [...]
Well, today’s subject isn’t a cheerful data set, but it certainly deserves some thought. Over at Pharmalot, Ed Silverman has some data from consulting firm AVOS Life Sciences, who have sat down to estimate how well various drug companies will do with revenue from new drugs over the next few [...]
Thanks to Pharmalot for drawing attention to an AVOS Life Sciences analysis of the future of big-cap pharma company revenue. The "replacement ratio" chart shows the extent to which each company is expected to replace dollars lost from declining products (mainly patent expirations) with revenue from products launched within the [...]
QDIS Blog |
August 20th, 2008 |
Email this
I came across this article recently and having worked for BMS years ago, I always find it interesting to see what the company is up to. For Bristol, steady course may be best navigation In the past I've not been very hot on some of the deal makings of BMS [...]
pharmalot |
August 18th, 2008 |
Email this
Company 2007 2012 Percent Change Schering-Plough 0.38 1.58 315.8% Amgen 4.50 1.46 -67.6% Bristol-Myers Squibb 1.08 0.84 -21.7% Wyeth 0.60 0.49 -18.2% Abbott Labs 1.73 0.42 75.7% Johnson & Johnson 0.39 0.38 -2.4% GlaxoSmithKline 0.27 0.32 17.3% Eli Lilly 6.64 0.29 -95.6% Novartis 2.27 0.27 -88.2% Merck 0.51 0.26 -49.0% [...]
FierceBiotech |
August 15th, 2008 |
Email this
Accelerator Corporation is at it again. The Seattle-based biotech investment and development firm has formed the Mirina Corporation, which will focus on developing drugs using Minor Groove Binder technology to affect cellular processes involving microRNAs. MicroRNA is one of two types of RNAi found in all human cells and affects [...]
MSN |
August 14th, 2008 |
Email this
The nation's biggest biotech company appears on an MSN Money list of stocks with momentum. Here are StockScouter's top picks.[...]
CNBC |
August 14th, 2008 |
Email this
Shares of Amgen Inc. got a boost Thursday after Goldman Sachs said the company is poised to accelerate its earnings growth. Read More Permalink[...]
Provide epidemiology support within the oncology therapeutic area. Responsibilities include: -Scientific contributions to product teams to understand the natural history of[...]
This candidate will be involved in patent application drafting and prosecution, drafting and negotiation of various research and licensing agreements in coordination with[...]
Job ID: amge-00026827 Basic Qualifications: -A high school diploma or GED certificate. -3 years of experience in administration coordination Preferred Qualifications: -Good[...]
Job ID: amge-00026836 Basic Qualifications: - Bachelor degree in marketing, statistics, social, behavioral sciences, or related field of study required - 6 or more years[...]
